284 related articles for article (PubMed ID: 33236108)
1. Discordant GH and IGF-1 Results in Treated Acromegaly: Impact of GH Cutoffs and Mean Values Assessment.
Campana C; Cocchiara F; Corica G; Nista F; Arvigo M; Amarù J; Rossi DC; Zona G; Ferone D; Gatto F
J Clin Endocrinol Metab; 2021 Mar; 106(3):789-801. PubMed ID: 33236108
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly.
Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B
J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329
[TBL] [Abstract][Full Text] [Related]
3. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
[TBL] [Abstract][Full Text] [Related]
4. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
[TBL] [Abstract][Full Text] [Related]
5. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
Carmichael JD; Bonert VS; Mirocha JM; Melmed S
J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
[TBL] [Abstract][Full Text] [Related]
6. Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?
Brzana JA; Yedinak CG; Delashaw JB; Gultelkin HS; Cook D; Fleseriu M
Pituitary; 2012 Dec; 15(4):562-70. PubMed ID: 22183781
[TBL] [Abstract][Full Text] [Related]
7. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly.
Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD
Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR.
Machado EO; Taboada GF; Neto LV; Haute FRV; Corrêa LL; Balarini GA; Shrank Y; Goulart M; Gadelha MR
Growth Horm IGF Res; 2008 Oct; 18(5):389-393. PubMed ID: 18348909
[TBL] [Abstract][Full Text] [Related]
9. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.
Gutt B; Hatzack C; Morrison K; Pöllinger B; Schopohl J
Eur J Endocrinol; 2001 Feb; 144(2):109-16. PubMed ID: 11182746
[TBL] [Abstract][Full Text] [Related]
10. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
11. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
12. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly.
Wang M; Shen M; He W; Yang Y; Liu W; Lu Y; Ma Z; Ye Z; Zhang Y; Zhao X; Lu B; Hu J; Huang Y; Shou X; Wang Y; Ye H; Li Y; Li S; Zhao Y; Zhang Z
Endocr J; 2016 Sep; 63(9):819-834. PubMed ID: 27432816
[TBL] [Abstract][Full Text] [Related]
13. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
[TBL] [Abstract][Full Text] [Related]
14. Dynamic tests and basal values for defining active acromegaly.
Tzanela M
Neuroendocrinology; 2006; 83(3-4):200-4. PubMed ID: 17047383
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
[TBL] [Abstract][Full Text] [Related]
16. [Lowered ghrelin levels in acromegaly—normalization after treatment].
Kozakowski J; Rabijewski M; Zgliczyński W
Endokrynol Pol; 2005; 56(6):862-70. PubMed ID: 16821203
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.
Freda PU; Post KD; Powell JS; Wardlaw SL
J Clin Endocrinol Metab; 1998 Nov; 83(11):3808-16. PubMed ID: 9814451
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
[TBL] [Abstract][Full Text] [Related]
20. Serum phosphate: Does it more closely reflect the true state of acromegaly?
Xie T; Tian P; Wu S; Zhang X; Liu T; Gu Y; Sun C; Hu F
J Clin Neurosci; 2020 Jan; 71():26-31. PubMed ID: 31859176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]